公开(公告)号：US20140271796A1

公开(公告)日：2014-09-18

申请号：US14354151

申请日：2012-10-23

Applicant: HISAMITSU PHARMACEUTICAL CO., INC.

Inventor： Kenji Atarashi ,  Kazuhiro Suzuki ,  Akio Takeuchi ,  Hidekazu Kuma

IPC: A61K31/575 ,  A61K31/235 ,  A61K9/70

CPC classification number: A61K31/575 ,  A61F2013/00646 ,  A61F2013/00906 ,  A61K9/0014 ,  A61K9/7023 ,  A61K9/7038 ,  A61K9/7053 ,  A61K9/7061 ,  A61K9/7084 ,  A61K9/7092 ,  A61K31/216 ,  A61K31/235 ,  A61K36/00 ,  A61K47/28 ,  A61K2300/00

Abstract: A transdermal absorption preparation containing at least one drug selected from oxybutynin and pharmaceutically acceptable salts thereof and 0.05% by mass or more of a sterol selected from cholesterols, cholesterol derivatives and cholesterol analogs, relative to a total amount of the transdermal absorption preparation.

Abstract translation: 相对于经皮吸收制剂的总量，含有选自奥昔布宁及其药学上可接受的盐中的至少一种药物和0.05质量％以上选自胆固醇，胆固醇衍生物和胆固醇类似物的固醇的透皮吸收制剂。

公开(公告)号：US09969688B2

公开(公告)日：2018-05-15

申请号：US15502793

申请日：2015-10-21

Applicant: HISAMITSU PHARMACEUTICAL CO., INC.

Inventor： Atsushi Sonobe ,  Takashi Yasukochi ,  Yasunori Takada ,  Kenji Atarashi ,  Motohiro Suzuki ,  Shinichi Yokota

IPC: C07D213/75

CPC classification number: C07D213/75 ,  A61K31/44

Abstract: The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein R is a hydrogen atom, a C1-6 alkyl group optionally substituted with one or more hydroxyl groups, a C1-6 alkoxy group, or a cyano group.